Department of Medicine, University of California, San Francisco, United States
Hanbing Song
Department of Medicine, University of California, San Francisco, United States
Wei Wu
Department of Medicine, University of California, San Francisco, United States
Rovingaile K Ponce
Department of Medicine, University of California, San Francisco, United States
Yone K Lin
Department of Medicine, University of California, San Francisco, United States
Ji Won Kim
Department of Medicine, University of California, San Francisco, United States
Eric J Small
Department of Medicine, University of California, San Francisco, United States; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, United States
Felix Y Feng
Department of Medicine, University of California, San Francisco, United States; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, United States; Department of Radiation Oncology, University of California, San Francisco, United States
Department of Medicine, University of California, San Francisco, United States; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, United States
Department of Medicine, University of California, San Francisco, United States; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, United States
Human prostate cancer can result from chromosomal rearrangements that lead to aberrant ETS gene expression. The mechanisms that lead to fusion-independent ETS factor upregulation and prostate oncogenesis remain relatively unknown. Here, we show that two neighboring transcription factors, Capicua (CIC) and ETS2 repressor factor (ERF), which are co-deleted in human prostate tumors can drive prostate oncogenesis. Concurrent CIC and ERF loss commonly occur through focal genomic deletions at chromosome 19q13.2. Mechanistically, CIC and ERF co-bind the proximal regulatory element and mutually repress the ETS transcription factor, ETV1. Targeting ETV1 in CIC and ERF-deficient prostate cancer limits tumor growth. Thus, we have uncovered a fusion-independent mode of ETS transcriptional activation defined by concurrent loss of CIC and ERF.
